Vnitr Lek 2005, 51(7-8):913-917

Haemovigilance

R. Procházková
Transfuzní oddělení Krajské nemocnice Liberec, prim. MUDr. Renata Procházková

Haemovigilance is a system of actions, comprising detection, summary and analysis of information concerning severe adverse effects and events on the part of transfusion donors and recipients and epidemiological monitoring of blood donors. In the complex conception a clinical section, which means transfusion indication criteria, their control, good practice in the course of transfusion administration, is also included in the definition. System of reporting of adverse effects of transfusions, which depends on clinical doctors knowledge and approach, is of a key importance. Superior legislative, procedure standards, operable network connecting state authorities, health care providers and transfusion service, further unmistakable data collection definition and application of findings to the practice is necessary for the effective haemovigilance system. Legislative standard for the European Union member states is Directive No. 2002/98/EC, which provides quality and safety standards for production of transfusion preparations, it does not solve the clinical section of problems. In the Czech Republic, the field of transfusion preparations production is quite well handled by the Medicine Act, while European legislative being implemented gradually. The situation in the clinical section is not optimal, especially national guidelines for indications of transfusion preparations and transfusion administration itself are missing, the problem is also the absence of undergraduate and postgraduate education in transfusiology.

Keywords: haemovigilance; transfusion safety; adverse effect

Received: April 14, 2005; Accepted: April 14, 2005; Published: July 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Procházková R. Haemovigilance. Vnitr Lek. 2005;51(7-8):913-917.
Download citation

References

  1. Directive 2002/98/EC of the European Parliament and of the Council setting standard of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and ammending Directive 2001/83/EC. Official J Eur Communities 2003.
  2. Faber JC. Worldwide overview of existing haemovigilance systems. Transf Apher Sci 2004; 31: 99-110. Go to original source... Go to PubMed...
  3. Guide on the preparation, use and quality assurance of blood components. Reccomendation No. R (95) 15, 9th ed. Council of Europe, January 2003.
  4. Robillard P, Chan P, Kleinman S. Hemovigilance for improvement of blood safety. Transf Apher Sci 2004; 31: 95-98. Go to original source... Go to PubMed...
  5. Zákon 79/1997 Sb. o léčivech a o změnách a doplnění některých souvisejících zákonů ve znění dalších novel.
  6. Vyhl. MZdr. 411/2004 Sb., kterou se stanoví správná výrobní praxe, správná distribuční praxe a bližší podmínky povolování výroby a distribuce léčiv, včetně medikovaných krmiv a veterinárních autologních vakcín, změn vydaných povolení, jakož i bližší podmínky vydávání povolení k činnosti kontrolních laboratoří (vyhláška o výrobě a distribuci léčiv).
  7. Zákon 123/2000 Sb. o zdravotnických prostředcích a o změně souvisejících zákonů.
  8. Vyhl. 424/2004 Sb., kterou se stanoví činnosti zdravotnických pracovníků a jiných odborných pracovníků.
  9. Ciavarella DJ, Harmening DM, Hoppe PA et al. Transfusion therapy: Clinical principles and practise. Bethesda: AABB Press 1999: 359-361.
  10. Procházková R, Masopust J. Návrh hlášení a vyšetření potransfuzních reakcí. Sborník abstrakt. 10. pracovní dny Společnosti pro transf. lékařství ČLS JEP, 8.-10. 9. 2004, Rožnov pod Radhoštěm.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.